Physician Spotlight: Alex Spira, M.D., PhD, F.A.C.P., Medical Oncologist

(44)

Dr. Alexander Spira Discusses Advances in Non-Small Cell Lung Cancer (NSCLC)

(1:16)

Immuno Forum Georgetown 2017 How Does Immunotherapy Work Spira

(15:31)

Dr. Spira on the POPLAR Study for NSCLC

(1:25)

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

(50)

Post-osimertinib landscape for NSCLC

(1:)

Should I Give up My Desire to Be Happy?

(14:3)

Why Is Simply Being Not Enough for Me?

(12:17)

The Self is an Illusion - Sam Harris

(23:46)

Sam Harris Takes His Anger Out on Joe Rogan After Trump Win

(2:9)

How Sam Harris Feels About His Split From Jordan Peterson

(12:38)

Is Everything Conscious? Within Reason #27

(2:7:37)

Sam Harris basically unlocks the secret to life

(4:24)

Exposing Scientific Dogmas - Banned TED Talk - Rupert Sheldrake

(17:32)

Lego City REAL FISH Deep Sea Exploration Vessel Adventure

(24:26)

Dr Popular Meeruthi [HD] at Latest INDOPAK Mushaira, Bhopal, 05-11-2015

(14:18)

First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander Spira

(58)

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

(34)

Alex Spira, MD, PhD, FACP, shares thoughts on the Phase I CHRYSALIS study presented at ESMO 2020

(1:37)

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

(15:35)

Modernization of clinical trial eligibility criteria

(1:39)

Developments and challenges in MET targeting for lung cancer

(1:50)

CANOPY-A: canakinumab for resected NSCLC

(1:30)

Alex Spira, MD, PhD, FACP, offers thoughts on the four-year follow-up to the Phase III PACIFIC trial

(1:40)

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC

(3:21)

DESTINY-Lung01: a practice-changing trial for NSCLC

(1:14)

Alex Spira, MD, PhD, FACP, discusses the mechanism of action of amivantamab (JNJ-6372)

(1:20)

Novel combinations in EGFR positive advanced NSCLC

(16:22)

Alexander Spira, MD, PhD, FACP, on how Virginia Cancer Specialists is embracing value-based care

(33)

Alexander Spira, MD, PhD, FACP, tells us the latest thinking regarding the PD-L1 biomarker

(45)